Fosamax Oct 14

Client Attorney Privileged/Attorney Work Product/At Request of Counsel

1. Would I Take Fosamax? Addressing A Question About Medication-Related Osteonecrosis Of The Jaw

   Oct 13, 2015 | Dentistry iQ

   By Maria Perno Goldie, RDH, MS
   
   
   I recently presented a webinar for Colgate entitled Women's Wellness: What a Difference an X Makes. I was asked a question on which I would like to elaborate. The question was on the osteoporosis medication, Fosamax, and any dental/oral concerns in patients that take this drug.
2. Sequential Tx With Anabolic Agent Cuts Fracture Risk

   Oct 13, 2015 | MedPage Today

   By Nancy Walsh
   
   
   A sequential strategy in which 18 months of treatment with abaloparatide was followed by 6 months of alendronate (Fosamax) among postmenopausal women has the potential to be a highly effective option, a researcher said here. In the initial 18 months of the ACTIVE trial, when women were randomized to receive 80 μg subcutaneous...

Full Text of Stories Below

Client Attorney Privileged/Attorney Work Product/At Request of Counsel

1. Would I Take Fosamax? Addressing A Question About Medication-Related Osteonecrosis Of The Jaw

   Oct 13, 2015 | Dentistry iQ

   By Maria Perno Goldie, RDH, MS

   I recently presented a webinar for Colgate entitled Women's Wellness: What a Difference an X Makes. I was asked a question on which I would like to elaborate.
   

   The question was on the osteoporosis medication, Fosamax, and any dental/oral concerns in patients that take this drug. I was asked if I, myself, would take this medication, if needed. My answer to that is that if I needed an osteoporosis medication, I would initially try a selective estrogen receptor modulator (SERM). In a three-year study involving 600 postmenopausal women, raloxifene (brand name: Evista) was found to increase bone density and lower LDL cholesterol. (1) However, everyone is different and must check with an endocrinologist or other physician.

   If one is taking certain osteoporosis medications and needs any kind of oral surgery, serious problems could occur. We were made aware of bisphosphonate-related osteonecrosis of the jaw (BRONJ), however, bisphosphonates are not the only culprits. An increasing number of osteonecrosis cases involving the maxilla and mandible have been associated with other antiresorptive (e.g., denosumab) and antiangiogenic therapies. (2) Therefore, the American Association of Oral and Maxillofacial Surgeons (AAOMS) feels it is more appropriate to label this condition medication-related osteonecrosis of the jaw (MRONJ). In 2013, a special committee met to evaluate the current literature and revise the 2009 guidelines to reflect current knowledge in this field. The update contains revisions to diagnosis, staging, and management strategies, and highlights current research status. (2)...

   For full story: http://www.dentistryiq.com/articles/2015/10/would-i-take-fosamax-addressing-medication-related-osteonecrosis-of-the-jaw-mronj.html
   

   Return to headline | Return to top

2. Sequential Tx With Anabolic Agent Cuts Fracture Risk

   Oct 13, 2015 | MedPage Today

   By Nancy Walsh

   A sequential strategy in which 18 months of treatment with abaloparatide was followed by 6 months of alendronate (Fosamax) among postmenopausal women has the potential to be a highly effective option, a researcher said here.

   In the initial 18 months of the ACTIVE trial, when women were randomized to receive 80 μg subcutaneous abaloparatide each day, placebo, or 20 μg of teriparatide, the abaloparatide arm had an 86% reduction in vertebral fracture risk. Advertisement

   Then, in the first 6 months of ACTIVExtend, when all patients were given alendronate, 70 mg/week, there were seven new vertebral fractures among patients who had received placebo (1.2%) and none in the group who had previously been given abaloparatide, which represented an 87% risk reduction with this treatment over the total study, reported Felicia Cosman, MD, of Helen Hayes Hospital in West Haverstraw, N.Y. at the American Society for Bone and Mineral Research meeting.

   The duration of anabolic therapy is limited to 18 to 24 months because of animal toxicology reports, but bone density declines when the therapy is discontinued and few studies have looked at the sequential use of an antiresorptive agent after anabolic therapy...

   For full story: http://www.medpagetoday.com/MeetingCoverage/ASBMR/54074
   

   Return to headline | Return to top

Full Text of Stories Below